ArticleBiomarker research2026

Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis.

Sagrario Corrales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.